Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 119,776
  • Shares Outstanding, K 15,760
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,820 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34
Trade ENLV with:

Options Overview

Details
  • Implied Volatility 143.43%
  • Historical Volatility 59.54%
  • IV Percentile 60%
  • IV Rank 25.80%
  • IV High 309.85% on 11/09/20
  • IV Low 85.57% on 07/06/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 71
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 5,018
  • Open Int (30-Day) 4,688

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.20 +12.49%
on 07/20/21
9.15 -11.49%
on 08/02/21
-0.80 (-9.00%)
since 07/02/21
3-Month
7.20 +12.49%
on 07/20/21
10.95 -26.04%
on 05/06/21
-2.86 (-26.10%)
since 05/05/21
52-Week
4.49 +80.38%
on 08/24/20
29.40 -72.45%
on 02/08/21
+2.53 (+45.40%)
since 08/05/20

Most Recent Stories

More News
Enlivex Hires Biotech Industry Veteran Tzvi Palash to Lead the Design and Construction of its New cGMP Allocetra Manufacturing Plant

Mr. Palash joins Enlivex from Gamida Cell, where he served as Chief Operating Officer, and previously served as Chief Operating Officer of Protalix Biotherapeutics, and as General Manager of ColBar LifeScience,...

ENLV : 8.25 (+0.86%)
Enlivex to Present at the Improvate Life-Saving Technologies International Conference 2021

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that its CEO, Dr. Oren Hershkovitz, will participate in, and provide...

ENLV : 8.25 (+0.86%)
Enlivex to Present at the ARDS Drug Development Summit 2021

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company will participate in, and present at, the ARDS...

ENLV : 8.25 (+0.86%)
Enlivex Initiates Design and Construction Process for a New cGMP Allocetra Manufacturing Plant

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it has initiated the design and construction process for a...

ENLV : 8.25 (+0.86%)
Enlivex Annouces Participation in A.G.P.'s Upcoming 2021 Virtual Summer Healthcare Symposium

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Company's management team will participate...

ENLV : 8.25 (+0.86%)
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 8.25 (+0.86%)
Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual...

ENLV : 8.25 (+0.86%)
Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 8.25 (+0.86%)
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021

ENLV : 8.25 (+0.86%)
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra(TM) in Combination with Immune Checkpoint Inhibitors

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END

ENLV : 8.25 (+0.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 9.34
2nd Resistance Point 9.06
1st Resistance Point 8.62
Last Price 8.25
1st Support Level 7.90
2nd Support Level 7.62
3rd Support Level 7.18

See More

52-Week High 29.40
Fibonacci 61.8% 19.88
Fibonacci 50% 16.94
Fibonacci 38.2% 14.01
Last Price 8.25
52-Week Low 4.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar